Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.67 - $3.19 $3.3 Million - $15.7 Million
-4,921,487 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.22 - $3.45 $136,057 - $211,440
61,287 Added 1.26%
4,921,487 $14.7 Million
Q4 2021

Feb 14, 2022

BUY
$2.36 - $3.57 $157,648 - $238,476
66,800 Added 1.39%
4,860,200 $12.9 Million
Q3 2021

Nov 15, 2021

BUY
$3.5 - $4.5 $134,750 - $173,250
38,500 Added 0.81%
4,793,400 $17.4 Million
Q2 2021

Aug 16, 2021

BUY
$3.09 - $4.54 $39,861 - $58,566
12,900 Added 0.27%
4,754,900 $20.6 Million
Q1 2021

May 17, 2021

SELL
$3.35 - $4.93 $2,984 - $4,392
-891 Reduced 0.02%
4,742,000 $16.2 Million
Q3 2020

Nov 16, 2020

SELL
$1.78 - $4.13 $2.06 Million - $4.77 Million
-1,154,751 Reduced 19.58%
4,742,891 $11.4 Million
Q2 2020

Aug 14, 2020

BUY
$1.41 - $2.05 $560,675 - $815,166
397,642 Added 7.23%
5,897,642 $10.8 Million
Q1 2020

May 15, 2020

BUY
$1.27 - $3.0 $2,667 - $6,300
2,100 Added 0.04%
5,500,000 $8.58 Million
Q4 2019

Feb 14, 2020

BUY
$1.6 - $2.43 $2.08 Million - $3.15 Million
1,297,900 Added 30.9%
5,497,900 $11.8 Million
Q4 2018

Feb 14, 2019

BUY
$2.08 - $3.36 $156,000 - $252,000
75,000 Added 1.82%
4,200,000 $9.66 Million
Q3 2018

Nov 14, 2018

BUY
$2.6 - $3.59 $455,000 - $628,250
175,000 Added 4.43%
4,125,000 $13.2 Million
Q2 2018

Aug 14, 2018

BUY
$2.83 - $4.11 $3.89 Million - $5.65 Million
1,375,000 Added 53.4%
3,950,000 $11.2 Million
Q1 2018

May 15, 2018

BUY
$3.54 - $4.54 $354,000 - $454,000
100,000 Added 4.04%
2,575,000 $9.12 Million
Q4 2017

Feb 14, 2018

BUY
$3.23 - $4.3 $4.76 Million - $6.34 Million
1,475,000 Added 147.5%
2,475,000 $9.6 Million
Q3 2017

Nov 14, 2017

BUY
$2.18 - $2.57 $2.18 Million - $2.57 Million
1,000,000
1,000,000 $2.54 Million

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.95B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.